Article citationsMore>>
A. A. Di Tucci, G. Matta, S. Deplano, et al., “Myocardial Iron Overload Assessment by T2* Magnetic Resonance Imaging in Adult Transfusion Dependent Patients with Acquired Anemias,” Haematologica, Vol. 93, No. 9, 2008, pp. 1385-1388.
[10] J. Chacko, D. J. Pennell, M. A. Tanner, et al., “Myocardial Iron Loading by Magnetic Resonance Imaging T2* in Good Prognostic Myelodysplastic Syndrome Patients on Long-Term Blood Transfusions,” British Journal Hae-matology, Vol. 138, No. 5, 2007, pp. 587-593.
doi:10.1111
has been cited by the following article:
-
TITLE:
Is Iron-Chelation Therapy Useful in Persons with Myelodysplastic Syndrome Receive?
AUTHORS:
Chaim Hershko, Robert Peter Gale
KEYWORDS:
Myelodysplastic Syndrome, MDS, Iron-Chelation, NTBI, Deferoxamine, Ddeferiprone, Deferasirox, Transfusion Siderosis
JOURNAL NAME:
Open Journal of Blood Diseases,
Vol.1 No.1,
September
20,
2011
ABSTRACT: Iron overload in myelodysplastic syndrome (MDS) results from multiple RBC-transfusions and inappropriate increased iron absoption associated with ineffective erythropoiesis. Data from hereditary iron-loading anemias indicate long-term consequences of iron toxicity are preventable and potentially reversible by effective iron-chelation therapy (ICT).
There is increasing interest in using ICT in persons with MDS because of the recent introduction of orally effective iron-chelators which are suitable for older persons, (1-4). Ideally, evidence supporting the benefit of ICT in MDS should be evidenced-based, especially data from randomized trials showing better survival and, in exceptional cases, improved heart function . Such data are lacking. Nevertheless, it is possible to rely on the extensive data from trials of ICT in persons with thalassemia and to use well-defined predictors of increased risks of life-threatening complications to identify persons with MDS most likely to benefit from iron-chelating therapy.